Bitter Melon (Momordica Charantia) Reduces Serum Sialic Acid in Type2 Diabetics: Evidence to Delay the Process of Atherosclerosis


More than 1000 herbal products have been used by diverse cultures of the world to treat hyperglycemia and among them bitter melon (Momordica charantia) is one of the most popular herbal resource. The beneficial effects of bitter melon is not limited to hypoglycaemia only, but it also ameliorates diet induced obesity, insulin resistance and exhibit cardioprotective effects. The present study attempts to investigate the effect of bitter melon fruit juice on a newly investigated risk factor, sialic acid in type2 diabetics. A total of 40 type2 diabetic patients, divided into group A (n = 20) and group B (n = 20) were investigated during the present study. The patients of group A were following bitter melon fruit juice treatment along with diet control, whereas the patients of group B were on diet control only. Serum sialic acid (SSA) decreased in group A from 66.20 ± 2.30 mg/dl to 63.50 ± 2.10 mg/dl (<0.11) but, increased in group B from 66.50 ± 1.70 mg/dl to 68.20 ± 2.50 mg/dl (<0.12), compared to baseline. Post-treatment between group comparison revealed a significant difference (<0.05). The beneficial effects on fasting plasma glucose (FPG) and glycohemoglobin (HbA1-c) were also greater in group A compared to group B as was the case with blood lipids, weight and blood pressure. The study provides another mechanism for the cardioprotective effect of bitter melon and further strengthens its value in the management of type2 diabetes.

Share and Cite:

Rahman, I. , Bashir, M. , Salman, M. , Idrees, M. and Khan, M. (2011) Bitter Melon (Momordica Charantia) Reduces Serum Sialic Acid in Type2 Diabetics: Evidence to Delay the Process of Atherosclerosis. Chinese Medicine, 2, 125-129. doi: 10.4236/cm.2011.24021.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] J. H. McNeill, “Experimental Models of Diabetes,” 1st Edition, CRC Press, Boca Raton, 1999.
[2] E. Basch, S. Gabardi and C. Ulbricht, “Bitter Melon (Momordica Charantia): A Review of Efficacy and Safety,” American Journal of Health-System Pharmacy, Vol. 60, No. 4, 2003, pp. 356-359.
[3] J. K. Grover and S. P. Yadav, “Pharmacological Actions and Potential Uses of Momordica Charantia, a Review,” Journal of Ethnopharmacology, Vol. 93, No. 1, 2004, pp. 123-132. doi:10.1016/j.jep.2004.03.035
[4] P. Chaturvedi, “Role of Momordica Charantia in Maintaining the Normal Levels of Lipids and Glucose in Diabetic Rats Fed a High-Fat and Low-Carbohydrate Diet,” British Journal of Biomedical Science, Vol. 62, No. 3, 2005, pp. 124-126.
[5] J. C. Pickup, M. B. Mattock, M. A. Crook, et al., “Serum Sialic Acid Concentration and Coronary Heart Disease in NIDDM,” Diabetes Care, Vol. 18, No. 8, 1995, pp. 1100-1103. doi:10.2337/diacare.18.8.1100
[6] J. C. Pickup, G. A. Roberts, A. M. Kehley, et al., “Higher Serum Sialic Acid in Women than in Men with NIDDM: Possible Relevance to Cardiovascular Risk in NIDDM Women,” Diabetes Care, Vol. 20, 1997, p. 1494.
[7] V. Vijay, C. Snehalatha, A. Ramachandran and M. Jayaraman, “Serum Sialic Acid in South Indian Type2 Diabetic Patients with Microvascular Complications,” Diabetic Medicine, Vol. 15, No. 2, 1998, p. 176. doi:10.1002/(SICI)1096-9136(199802)15:2<176::AID-DIA553>3.0.CO;2-A
[8] N. Abdella, A. O. Akanji, O. A. Mojiminiyi, et al., “Relation of Serum Total Sialic Acid Concentrations with Diabetic Complications and Cardiovascular Risk Factors in Kuwaiti Type2 Diabetic Patients,” Diabetes Research and Clinical Practice, Vol. 50, No. 1, 2000, pp. 65-72. doi:10.1016/S0168-8227(00)00144-3
[9] M. Crook, P. Tutt, H. Simpson and J. C. Pickup, “Serum Sialic Acid and Acute Phase Proteins in Type1 and Type2 Diabetes Mellitus,” Clinica Chemica Acta, Vol. 219, No. 1-2, 1993, pp. 131-138. doi:10.1016/0009-8981(93)90204-H
[10] K. Taniuchi, K. Chifu, N. Hayashi, et al., “A New Enzymatic Method for the Determination of Sialic Acid and Its Application as a Marker of Acute Phase Reactants,” Kobe Journal of Medical Sciences, Vol. 27, 1981, pp. 91-102.
[11] D. Thompson, S. P. Hrrison, S. W. Evans and J. T. Whicher, “Insulin Modulation of Acute Phase Protein Production in a Human Hepatoma Cell Line,” Cytokine, Vol. 3, No. 6, 1991, pp. 619-626. doi:10.1016/1043-4666(91)90489-Z
[12] M. Haq, S. Haq, P. Tutt and M. Crook, “Serum Total Sialic Acid and Lipid Associated Sialic Acid in Normal Individuals and Patients with Myocardial Infarction and Their Relationship to Acute Phase Proteins,” Annals of Clinical Biochemistry, Vol. 30, 1993, pp. 383-386.
[13] S. P. Campos and H. Baumann, “Insulin Is a Prominent Modulator of the Cytokine Stimulated Expression of Acute Phase Plasma Proteins,” Molecular and Cellular Biology, Vol. 12, 1992, pp. 1789-1797.
[14] M. D. Flynn, R. J. M. Corrall, P. J. Waters and C. A. Pennock, “Sialic Acid and Cardiovascular Mortality,” British Medical Journal, Vol. 302, 1991, pp. 533-534. doi:10.1136/bmj.302.6775.533-c
[15] A. G. Morell, G. Gregoriadis, I. H. Scheinberg, et al., “The Role of Glycoproteins in the Circulation,” The Journal of Biological Chemistry, Vol. 246, 1971, pp. 1461-1467.
[16] M. A. Crook, K. Earle, A. Morocutti, et al., “Serum Sialic Acid, a Risk Factor for Cardiovascular Disease, Is Increased in IDDM Patients with Microalbuminuria and Clinical Proteinuria,” Diabetes Care, Vol. 17, No. 4, 1994, pp. 305-309. doi:10.2337/diacare.17.4.305
[17] A. Vaya, C. Falco, E. Reganon, et al., “Influence of Plasma and Erythrocyte Factors on Red Blood Cell Aggregation in Survivors of Acute Myocardial Infarction,” Thromb Haemostas, Vol. 91, 2004, pp. 354-359.
[18] R. J. Shamberger, “Serum Sialic Acid in Normal and Cancer Patients,” Journal of Clinical Chemistry & Clinical Biochemistry, Vol. 22, 1984, pp. 64-67.
[19] World Health Organization, “Diet, Nutrition and the Prevention of Chronic Diseases,” Report of a WHO Study Group, Technical Report Series 1990, No. 797, World Health Organization, Geneva, 1990.
[20] J. D. Cohen, R. H. Grimm and W. M. Smith, “The Multiple Risk Factor Intervention Trial (MRFIT) 4: Intervention on Blood Pressure,” Preventive Medicine, Vol. 10, No. 4, 1981, pp. 501-518. doi:10.1016/0091-7435(81)90062-1
[21] World Health Organization Expert Committee, “Arterial Hypertension,” Technical Report Series, No. 628, WHO, Geneva, 1978.
[22] A. D. Paterson, B. N. Rutledge, P. A. Cleary, et al., “The Effect of Intensive Diabetes Treatment on Resting Heart Rate in Type1 Diabetes: The Diabetes Control and Complications Trial (DCCT), Epidemiology of Diabetes Interventions and Complications Study,” Diabetes Care, Vol. 30, No. 8, 2007, pp. 2107-2112. doi:10.2337/dc06-1441
[23] G. Lindberg, L. Rastam, B. O. Gullber and G. A. Eklund, “Serum Sialic Acid Concentration Predicts Coronary Heart Disease and Stroke Mortality: Multivariate Analysis Including 54385 Men and Women during 30.5 Years Follow-up,” International Journal of Epidemiology, Vol. 21, No. 2, 1992, pp. 253-257. doi:10.1093/ije/21.2.253
[24] M. W. Knuiman, G. F. Watts and M. L. Divitini, “Is Sialic Acid an Independent Risk Factor for Cardiovascular Disease: A 17 Year Follow-up Study in Busselton, Western Australia,” Annals of Epidemiology, Vol. 14, No. 9, 2004, pp. 627-632. doi:10.1016/j.annepidem.2003.09.017
[25] M. Pfeifer, R. Verhovee, B. Zizek, et al., “Growth Hormone Reverses Early Atherosclerotic Changes in Growth Hormone Deficient Adults,” The Journal of Clinical Endocrinology & Metabolism, Vol. 84, No. 2, 1999, pp. 453-457. doi:10.1210/jc.84.2.453
[26] C. L. Hsieh, Y. C. Lin, W. S. Ko, et al., “Inhibitory Effect of Some Selected Nutraceutic Herbs on LDL Glycation Induced by Glucose and Glyoxal,” Journal of Ethnopharmacology, Vol. 102, No. 3, 2005, pp. 357-363. doi:10.1016/j.jep.2005.06.044
[27] N. M. Ansari, L. Houlihan, B. Hussain and A. Pieroni, “Antioxidant Activity of Five Vegetables Traditionally Consumed by South-Asian Migrants in Bradford, Yorkshire, UK,” Phytotherapy Research, Vol. 19, No. 10, 2005, pp. 907-911. doi:10.1002/ptr.1756
[28] D. M. Lee, W. H. Hoffman, G. F. Carl, et al., “Lipid Peroxidation and Antioxidant Vitamins Prior to, during, and after Correction of Diabetic Ketoacidosis,” Journal of Diabetes and Its Complications, Vol. 16, No. 4, 2002, pp. 294-300. doi:10.1016/S1056-8727(01)00215-X
[29] L. L. Chan, Q. Chen, A. G. G. Go, E. K. Y. Lam and E. S. T. Li, “Reduced Adiposity in Bitter Melon (Momordica Charantia)-Fed Rats Is Associated with Increased Lipid Oxidative Enzyme Activities and Uncoupling Protein Expression,” Biochemical and Molecular Actions of Nutrients, Vol. 135, No. 11, 2005, pp. 2517- 2523.
[30] I. Ahmad, M. S. Lakhani, M. Gillett, et al., “Hypotriglyceridemic and Hypocholesterolemic Effects of Antidiabetic Momordica Charantia (Karela) Fruit Extract in Streptozotocin Induced Diabetic Rats,” Diabetes Research and Clinical Practice, Vol. 51, No. 3, 2001, pp. 155-161. doi:10.1016/S0168-8227(00)00224-2
[31] M. Crook, P. Lumb, V. Andrews and R. Swaminathan, “Serum Total Sialic Acid, a Reputed Cardiovascular Risk Factor, and Its Relationship to Lipids, Plasma Fasting Insulin, Blood Pressure and Body Mass Index in Normal Individuals,” Clinical Science, Vol. 95, 1998, pp. 53-57. doi:10.1042/CS19970239
[32] S. S. Dhanasekar and S. Subramanian, “Antioxidant Properties of Momordica Charantia (Bitter Gourd) Seeds on Streptozotocin Induced Diabetic Rats,” Asia Pacific Journal of Clinical Nutrition, Vol. 14, No. 2, 2005, pp. 153-158.
[33] R. Gebhardt, “Antioxidative, Antiproliferative and Biochemical Effects in HepG2 Cells of a Homeopathic Remedy and Its Constituent Plant Tinctures Tested Separately or in Combination,” Arzneimittelforschung, Vol. 53, No. 12, 2005, pp. 823-830.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.